iRadimed (IRMD)
(Delayed Data from NSDQ)
$50.41 USD
+1.32 (2.69%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $50.40 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$50.41 USD
+1.32 (2.69%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $50.40 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Zacks News
IRadimed (IRMD) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 33.33% and 3.55%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
IRadimed (IRMD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRadimed (IRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRADIMED (IRMD) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
IRADIMED (IRMD) reports growth across all operating segments and geographies
IRadimed (IRMD) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 23.08% and 1.82%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
IRadimed (IRMD) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Buy Stocks for December 17th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
New Strong Buy Stocks for December 5th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
IRadimed (IRMD) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
iRadimed (IRMD) delivered earnings and revenue surprises of 40.00% and 2.52%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
IRadimed (IRMD) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
IRadimed (IRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Best ETFs & Stocks From the Top Sector of Q3
by Sweta Killa
Healthcare was the best-performing sector of the third quarter, jumping 14.1% - its highest quarterly gain since the first quarter of 2013.
iRadimed Corporation (IRMD) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
iRadimed Corporation (IRMD) Sees Hammer Chart Pattern: Time to Buy?
Top Ranked Momentum Stocks to Buy for May 29th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 29th:
Zacks.com featured highlights include: Lindblad, Cleveland-Cliffs, Marine Products, IRadimed and ChannelAdvisor
by Zacks Equity Research
Zacks.com featured highlights include: Lindblad, Cleveland-Cliffs, Marine Products, IRadimed and ChannelAdvisor
5 Breakout Stocks Offering Extraordinary Returns
by Swarup Gupta
This technique seeks to identify those stocks whose prices are varying within a specific band.
IDEXX (IDXX) Hits a 52-Week High, Can the Run Continue?
by Zacks Equity Research
IDEXX Laboratories, Inc. is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for IDXX for clues.
IRadimed (IRMD) Hits 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Positive tidings on the regulatory front drive IRadimed's (IRMD) growth. The company's solid guidance is also encouraging.
Zacks.com featured highlights: Stoneridge, Synthetic Biologics, IRadimed Corporation, Syntel and AXT
by Zacks Equity Research
Zacks.com featured highlights: Stoneridge, Synthetic Biologics, IRadimed Corporation, Syntel and AXT
5 Cheap Breakout Stocks Offering Strong Returns
by Swarup Gupta
This technique seeks to identify those stocks whose prices are varying within a specific band.
IRADIMED (IRMD) MRidium Magnetic MRI Gets FDA Approval
by Zacks Equity Research
IRADIMED CORPORATION (IRMD) recently announced the receipt of 510(k) clearance for its MRidium 3860+ magnetic MRI compatible IV infusion pump system, which features the Dose Error Reduction System software (DERS).
4 Medical Instrument Makers to Save Your Portfolio
by Jeremy Mullin
Technology in the medical world is leading these companies to breakthrough devices, which save and extend lives.